NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. The event provides a platform for the company to discuss its strategic direction and the progress of its lead drug candidate, NV-387.
NV-387 is a broad-spectrum antiviral drug designed to treat respiratory viral infections, including RSV, COVID-19, Long COVID, influenza, and other respiratory viruses. The drug has also shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. According to the company, NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, positioning it for advancement into Phase II trials.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's other advanced drug candidate, NV-HHV-1, targets all Herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (shingles), and chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application due to reliance on external collaborators and consultants.
The D. Boral Capital Global Conference offers NanoViricides an opportunity to engage with the investment community and highlight its unique approach to antiviral therapy. The company's nanomaterial-based platform aims to address unmet medical needs in treating viral diseases that have limited treatment options. The participation in this conference is significant as it may attract potential investors and partners interested in the development of broad-spectrum antivirals.
For more information about NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC. The full press release regarding the conference participation is available at https://ibn.fm/YxQydA.
